studies

mBC-Triple negative (TNBC) - 2nd Line (L2), anti-PD-(L)1 vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-119 (all population), 2019 0.97 [0.82; 1.15] KEYNOTE-119 (PDL1 CPS>1), 2019 0.86 [0.69; 1.07] KEYNOTE-119 (PDL1 CPS>10), 2019 0.78 [0.57; 1.06] 0.90[0.80; 1.02]KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 201930%1,221moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-119 (all population), 2019 1.60 [1.33; 1.92] KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [1.08; 1.68] KEYNOTE-119 (PDL1 CPS>10), 2019 1.14 [0.82; 1.59] 1.40[1.17; 1.68]KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019343%1,221moderatenot evaluable DCRdetailed resultsKEYNOTE-119 (all population), 2019 0.60 [0.39; 0.94] 0.60[0.39; 0.94]KEYNOTE-119 (all population), 201910%622NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-119 (all population), 2019 0.89 [0.53; 1.50] KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [0.72; 2.54] KEYNOTE-119 (PDL1 CPS>10), 2019 2.13 [0.90; 5.04] 1.25[0.79; 1.99]KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019335%1,221moderatenot evaluable SAE (any grade)detailed resultsKEYNOTE-119 (all population), 2019 0.99 [0.66; 1.48] 0.99[0.66; 1.48]KEYNOTE-119 (all population), 201910%601NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.29 [0.19; 0.43] 0.29[0.19; 0.43]KEYNOTE-119 (all population), 201910%601NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.37; 2.41] 0.94[0.37; 2.41]KEYNOTE-119 (all population), 201910%601NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-119 (all population), 2019 1.05 [0.42; 2.63] 1.05[0.42; 2.63]KEYNOTE-119 (all population), 201910%601NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.28 [0.08; 1.01] 0.28[0.08; 1.01]KEYNOTE-119 (all population), 201910%601NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.26 [0.28; 5.69] 1.26[0.28; 5.69]KEYNOTE-119 (all population), 201910%601NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Cough TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.23 [0.05; 1.10] 0.23[0.05; 1.10]KEYNOTE-119 (all population), 201910%601NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.19; 4.72] 0.94[0.19; 4.72]KEYNOTE-119 (all population), 201910%601NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.05 [0.00; 0.79] 0.05[0.00; 0.79]KEYNOTE-119 (all population), 201910%601NAnot evaluable Headache TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.91 [0.57; 6.42] 1.91[0.57; 6.42]KEYNOTE-119 (all population), 201910%601NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02] 1.90[0.17; 21.02]KEYNOTE-119 (all population), 201910%601NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.09 [0.01; 1.71] 0.09[0.01; 1.71]KEYNOTE-119 (all population), 201910%601NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60] 5.72[0.29; 114.60]KEYNOTE-119 (all population), 201910%601NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsOut of scaleKEYNOTE-119 (all population), 2019 0.01 [0.00; 0.12] 0.01[0.00; 0.12]KEYNOTE-119 (all population), 201910%601NAnot evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.13 [0.02; 1.08] 0.13[0.02; 1.08]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23] 0.24[0.01; 5.23]KEYNOTE-119 (all population), 201910%601NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.16 [0.01; 3.13] 0.16[0.01; 3.13]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pneumonia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23] 0.24[0.01; 5.23]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60] 5.72[0.29; 114.60]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02] 1.90[0.17; 21.02]KEYNOTE-119 (all population), 201910%601NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Urticaria TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.04; 5.22] 0.47[0.04; 5.22]KEYNOTE-119 (all population), 201910%601NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:26 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 270,140,240 - treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563